Pentraxin 3 as a Novel Marker Predicting Congestive Heart Failure in Subjects With Acute Coronary Syndrome

다국어 초록 (Multilingual Abstract)

Background and Objectives: Pentraxin 3 (PTX3) was shown to be elevated in the acute phase of acute myocardial infarction (AMI) and to have prognostic significance in AMI patients. The aim of this study was to estimate whether the value of PTX3 could be used as a prognostic biomarker, with the global registry of acute coronary events (GRACE) risk assessment tool, in patients with acute coronary syndrome (ACS). Subjects and Methods: Between July 2007 and June 2008, 137 patient subjects (mean age : 61±12 years, M : F=108 : 29) with ACS who underwent coronary intervention, but did not have a prior percutaneous coronary intervention (PCI) and/or follow-up coronary angiogram, were enrolled. We estimated the allcause mortality or death/MI, in-hospital and to 6 months, using the GRACE risk scores and compared these estimates with serum PTX3 concentrations. Results: The serum PTX3 concentration showed a significant increase in ST segment elevation myocardial infarction (STEMI) greater than the unstable angina pectoris (UAP) group (2.4±2.1 ng/mL vs. 1.3±0.9 ng/mL, p= 0.017, respectively), but did not show a significant difference between non-ST segment elevation myocardial infarction (NSTEMI) and the UAP group (1.9±1.4 ng/mL vs. 1.3±0.9 ng/mL, p=0.083, respectively). The serum PTX3 concentration was closely related to death/MI in-hospital (r=0.242, p=0.015) and death/MI to 6 months (r=0.224, p=0.023), respectively. The serum PTX3 concentration was not related to all-cause mortality in-hospital (r=0.112, p=0.269) and to 6 months (r=0.132,p=0.191), respectively. Among the parameters determining the GRACE risk scores, the degree of Killip class in congestive heart failure (CHF) was independently associated with the supramedian PTX3 concentration [odds ratio: 2.229 (95% confidence interval: 1.038-4.787), p=0.040]. Conclusion: The serum PTX3 level provides important information for the risk stratification of CHF among the parameters determining the GRACE risk scores in subjects with ACS.

참고문헌 (Reference)

1 노혜진, "대사증후군 위험인자 집적도, hs-CRP, 죽상동맥 경화증의연관성 고찰" 대한심장학회 36 (36): 802-808, 2006

2 Doo YC, "The optimal timing to measure C-reactive protein to predict cardiac events in patients with unstable angina" 31 : 290-296, 2001

3 "The British Cardiac Society Working Group definition of myocardial infarction:implications for practice" 92 : 21-26, 2006

4 Kim TI, "Short-term prognostic value of CRP in the patients with acute coronary syndrome" 30 : 1387-1394, 2000

5 Rossi E, "Risk of myocardial infarction and angina in patients with severe peripheral vascular disease:predictive role of C-reactive protein" 105 : 800-803, 2002

6 GRACE Investigators, "Rationale and design of the GRACE(global registry of acute coronary events)project:a multinational registry of patients hospitalized with acute coronary syndrome" 141 : 190-199, 2001

7 Kotooka N, "Prognostic value of pentraxin 3 in patients with chronic heart failure" 130 : 19-22, 2008

8 Latini R, "Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction" 110 : 2349-2354, 2004

9 Rolph MS, "Production of the long pentraxin PTX3 in advanced atherosclerotic plaques" 22 : e10-e14, 2002

10 Haverkate F, "Production of C-reactive protein and risk of coronary events in stable and unstable angina.European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group" 349 : 462-466, 1997

11 Granger CB, "Predictors of hospital mortality in the global registry of acute coronary events" 163 : 2345-2353, 2003

12 Eagle KA, "Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction:findings from the global registry of acute coronary events(GRACE)" 359 : 373-377, 2002

13 Garlanda C, "Pentraxins at the crossroads between innate immunity,inflammation,matrix deposition,and female fertility" 23 : 337-366, 2005

14 Kotooka N, "Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening" 197 : 368-374, 2008

15 Suzuki S, "Pentraxin 3,a new marker for vascular inflammation,predicts adverse clinical outcomes in patients with heart failure" 155 : 75-81, 2008

16 Peri G, "PTX3,a prototypical long pentraxin,is an early indicator of acute myocardial infarction in humans" 102 : 636-641, 2000

17 de Beer FC, "Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction" 47 : 239-243, 1982

18 Scirica BM, "Is C-reactive protein an innocent bystander or proatherogenic culprit?:the verdict is still out" 113 : 2128-2134, 2006

19 Verma S, "Is C-reactive protein an innocent bystander or proatherogenic culprit?:C-reactive protein promotes atherothrombosis" 113 : 2135-2150, 2006

20 Bassand JP, "Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes" 28 : 1598-1660, 2007

21 Inoue K, "Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris" 27 : 161-167, 2007

22 Salio M, "Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction" 117 : 1055-1064, 2008

23 Smith SC Jr, "ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)" 47 : e1-e121, 2006

24 Anderson JL, "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STElevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction)developed in collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine" 50 : e1-e157, 2007

25 Eagle KA, "A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry" 291 : 2727-2733, 2004

26 King SB 3rd, "2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines" 51 : 172-209, 2008

27 King SB 3rd, "2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention:a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines:2007 Writing Group to Review New Evidence and Update the ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention,Writing on Behalf of the 2005 Writing Committee" 117 : 261-295, 2008

28 Antman EM, "2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians:2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction,Writing on Behalf of the 2004 Writing Committee" 117 : 296-329, 2008